Drug Trial Radar · NCT03534453
Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
225
Actual
Start
May 29, 2018
Primary completion
Jan 27, 2025
Study completion Jan 27, 2025
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- May 23, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, open-label, single arm, multi-centre interventional study to assess the clinical efficacy and safety of olaparib maintenance monotherapy and will be conducted in patients with platinum sensitive relapsed (PSR) high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy
Conditions
- Relapsed Ovarian Cancer
- Following Complete or Partial Response to Platinum Based Chemotherapy
- Platinum Sensitive
Interventions
Olaparib 300mg tabletsDrug
300mg Olaparib tablets taken orally twice daily until objective radiological disease progression as per RECIST as assessed by the investigator (or as long as in the investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria). Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS)Time frame: Time from first dose of olaparib until the date of investigator assessed disease progressionaccording to RECIST 1.1 criteria or death, whichever came first,up to 79 months
Locations
25 sites in 2 countries. Site status is shown where the registry gives one.
Research Site
Beijing, China
Research Site
Changsha, China
Research Site
Chengdu, China
Research Site
Chongqing, China
Research Site
Chongqing, China
Research Site
Hangzhou, China
Research Site
Hangzhou, China
Research Site
Harbin, China
Research Site
Hefei, China
Research Site
Jinan, China
Research Site
Shanghai, China
Research Site
Shanghai, China
Research Site
Shanghai, China
Research Site
Shenyang, China
Research Site
Tianjin, China
Research Site
Tianjin, China
Research Site
Wuhan, China
Research Site
Wuhan, China
Research Site
Xi'an, China
Research Site
Zhengzhou, China
Research Site
Ampang, Malaysia
Research Site
Johor Bahru, Malaysia
Research Site
Kuala Lumpur, Malaysia
Research Site
Kuching, Malaysia
Research Site
Putrajaya, Malaysia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.